original article on the preparation of transferrin ...on the preparation of transferrin modified...

Int J Clin Exp Med 2015;8(12):22045-22052www.ijcem.com /ISSN:1940-5901/IJCEM0016945

Original ArticleOn the preparation of transferrin modified artesunate nanoliposomes and their glioma-targeting treatment in-vitro and in-vivo

Huaiyu Tong1*, Yan Wang2*, Xuechun Lu3, Peng Wang1, Shupeng Zhao4, Haigang Chang4, Xinguang Yu1

1Department of Neurosurgery, PLA General Hospital, Beijing 100853, China; 2Department of Neurosurgery, The First Affiliated Hospital of PLA General Hospital, Beijing 100853, China; 3Department of Hematology, PLA General Hospital, Beijing 100853, China; 4Department of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, Henan Province, China. *Equal contributors.

Received September 26, 2015; Accepted December 8, 2015; Epub December 15, 2015; Published December 30, 2015

Abstract: Objective: To prepare transferrin modified artesunate nanoliposomes (Tf-ART-LPs) and study their glioma U87 cells-targeting treatment in-vitro and in-vivo. Methods: Ammonium sulfate transmembrane gradient method was used to prepare Tf-ART-LPs, whose size and stability was detected by a Nanosizer. Besides, the encapsulation efficiency and release rate of artesunate (ART) were tested by a ultraviolet spectrophotometer. Further, isothiocya-nate (FITC) was used to label nanoliposomes and the cell-targeting property of Tf-ART-LP in-vitro was observed under a fluorescence microscope. In addition, CCK-8 method was used to detect the effect of single nanoliposomes and Tf-ART-LPs on the viability of glioma U87 cells. At last, a subcutaneously implanted tumor model in nude mouse was established for studying the in-vivo anti-tumor effect of Tf-ART-LPs by caudal vein injection. The tumor volume and mice weight were monitored and pathological sections of their major organs were analyzed. Results: Tf-ART-LPs were spherical with an average diameter of 94.2 nm. They showed no aggregation after being stored in a refrigerator for 14 days at 4°C. The encapsulation efficiency and highest releasing rate (48 hours after being placed in normal saline under 37°C) of ART was 85.9% and 58.7±2.9%, respectively. The uptake rate of U87 cells was 59.8±3.8% for Tf-ART-LPs and only 18.7±4.5% for ART-LPs. While single liposomes almost showed no toxicity, Tf-ART-LP had a concentration-dependent killing effect on U87 cells. Within 32 days of treatment, the growth of U87 cells was well in-hibited by Tf-ART-LPs without significant toxicity. Conclusion: In this study, transferrin modified artesunate liposomes we prepared have a good targeting property to glioma U87 cells and good effect on glioma both in-vitro and in-vivo.

Keywords: Artesunate, transferrin, nanoliposome, ammonium sulfate transmembrane gradient method, targeting

Artesunate (ART) is one of the major derivatives of artemisinin with the structure of peroxide bridge. It was firstly isolated from Artemisia annual. feverfew by Chinese scientists in 1972. Being highly efficient in antimalaric treatment, it has been widely used for treating malignant warts, cerebral blisters and other chloroquine-resistant diseases [1, 2]. In recent years, inves-tigators have found that ART is of good in-vitro anti-tumor effect, which is increasingly valued [3, 4]. It is reported that artemisinin-based drugs have many strengths in anti-tumor treat-ment, including its selective inhibiting effect on multiple tumor cells, good tolerance and little toxicity [5]. Although the anti-tumor effect of artemisinin derivatives has been recognized internationally, its clinical application is restrict-

ed because of poor compliance of patients due to its high frequency of administration required (since it both takes effect and is eliminated quickly, the effective half-life is only 30 min-utes) [6]. Therefore, researches on sustained release preparation of artesunate are particu-larly important for its clinical use.

Nanoliposomes are drug carriers with cell-like structure. Drugs, once being encapsulated by liposomes, will be characterized by the follow-ing properties. Firstly, they have a certain pas-sive targeting property. Besides, they can be modified by targeting molecules on the surface of liposomes, which can interact specifically with complementary molecules on the surface of target cells, like receptors, via ligand mole-

http://www.ijcem.com

Transferrin modified artesunate nanoliposomes for neuroglioma targeting and therapy

22046 Int J Clin Exp Med 2015;8(12):22045-22052

cules in vivo. In this way, they can release drugs in target regions. Secondly, they have a long-term effect. Since drugs are encapsulated in liposomes, renal excretion and metabolism will be reduced. Thus, the residence time of drugs in blood will be prolonged and drugs can then be released slowly within human body, length-ening their acting time. Thirdly, they have tissue and cell compatibility. Since liposomes are vesicles resembling the structure of biological membrane, they are of good cell affinity and histocompatibility [7, 8]. Hereby, nanolipo-somes are the first choice to be used as carri-ers for ART. Jin Meihua et al. found out that ART encapsulated in liposomes was of good killing effect on human hepatoma cells HepG2 [9]. However, the active targeting property of ART has rarely been investigated. Furthermore, whether it is effective for more tumor cells is still unknown.

In this study, ART was enveloped by nanolipo-somes, the surface of which was modified by a targeting protein-transferrin. This protein can specifically bind with transferrin receptors high-ly expressed on the surface of tumor cells. In this way, anti-tumor drugs can then be trans-ferred to the tumor site specifically, achieving an active targeting effect [10, 11]. By using glioma U87 cells as the object of study, we explored the anti-tumor effect of artesunate nanoliposomes both in-vitro and in-vivo.

Materials and methods

Major reagents

Artesunate (ART, CAS: 88495-63-0), the crude drug, was purchase from Wuhan Dong Kang- yuan Technology Co., Ltd. (≥99.5% [HPLC]), lecithin, cholesterol, DSPE-PEG2000 and fluores-cein isothiocyanate (FITC) from Sigam (US), MEM culture medium, trypsin, fetal calf serum and phosphate buffer (PBS) from Gibco (US), penicillin-streptomycin mixed solution (100× double antibody) from Beijing Leagene Biotech. Co., Ltd., Cell Counting Kit (CCK-8) from YEASEN (Shanghai) and transferring (Tf) from Invitrogen (US).

Main instruments

Cell incubator HERAcell240i was purchased from Thermo (US), automatic inverted fluores-cence microscope Axio Observer Z1 from Carl

Zeiss AG (German), rotatory evaporator YRE-2020Z and lyophilizer LGJ-1 from Henan Yu- hua Instruments Co., Ltd., microplate reader MLDEL680 from Bio-Rad (US) and laser parti-cle size analyzer Nanosizer from Malvern Instruments Ltd.

Cell lines and cell culture

U-87 cells were star-shaped human brain glio-blastoma cells (hereafter referred to as glioma cells in short). Epithelioid cells were obtained from the cell resource center of Shang- hai Institutes for Biological Sciences, Chinese Academy of Science. These cells were cultured in a MEM culture medium with 10% fetal calf serum and 1% double antibody in an incubator under 37°C.

Laboratory animals

4-6 weeks old BALB/c-nu nude mice (half males and half females) with their body weight ranging from 20 to 25 g were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. The test began after they were fed on SPF for a week.

Test methods

The preparation of Tf-ART-LPs: In this study, ammonium sulfate transmembrane gradient method was adopted to prepare Tf-ART-LP according to the following three steps. Step one: A prescribed mixture of lecithin, choles-terol and DSPE-PEG2000 with mass ratio of 60:20:3 was dissolved in chloroform; The resul-tant substance was then placed in a rotary evaporator and was evaporated at 50°C until film formation was observed; Afterwards, chlo-roform was removed by reduced pressure evaporation, followed by the addition of 300 mM ammonium sulfate solution to hydrate properly; The resultant milk white suspension was crushed by an ultrasonic cell crusher for 10 mins and the blank liposome suspension was obtained. Step two: Excessive ART was added into the liposome obtained; The mixture was then heated to 50°C; After reaction for 30mins, ultra filtration was used to remove free ART; ART liposomes were thus gained. Step three: Sulfated transferrin was added into ART liposomes; The resultant mixture was react- ed overnight at room temperature; Then, free transferrins were removed by Sephadex CL-48


22047 Int J Clin Exp Med 2015;8(12):22045-22052

gel-filtration; Tf-ART-LPs were thus obtained and stored at 4°C.

Characterization of Tf-ART-LPs: Particle size distribution and stability of Tf-ART-LPs were detected by a Nanosizer. Their encapsulation efficiency was measured as follows. A certain amount of liposome solution was put into a dialysis bag. The bag was then immersed in PBS buffer solution. After magnetic stirring for 3 hs, the absorbance at 238 nm was detect-ed with an ultraviolet spectrophotometer. The encapsulation efficiency was then calculated according to ambert-beer’s law. The release rate of ART in normal saline was detected by the same method.

Test on the targeting property of Tf-ART-LPs: ART-LPs and Tf-ART-LPs, marked by FITC, were incubated with glioma U87 cells for 3 h. After

extracellular liposomes were washed away by PBS, they were imaged under a fluorescence microscope. The excitation wavelength was 488 nm.

Cytotoxicity test: First of all, the impact of blank LPs and Tf-LPs on cell viability was detected. Cells in logarithmic phase were transferred into a 96-well plate. After 24 hours, 0-100 ug/ml LPs and Tf-LPs were added and the mixture was incubated for another 24 hours. Then, 10% CCK-8 culture solution was added and the resultant solution was incubated for 30 mins. Finally, it was placed into a microplate reader to detect the absorbance at 450 nm (OD450 nm). Next, the same method was used to detect the impact of ART-LPs and Tf-ART-LPs on the viabil-ity of U87 cells.

The establishment of a subcutaneously implanted tumor model in nude mouse with glio-ma and its in-vivo treatment: U87 cells in loga-rithmic phase collected were prepared as sin-gle-cell suspension (107 cells/ml). For each nude mouse, 200 ul single-cell suspension was injected subcutaneously at the right lower back. The condition of these mice was observed every day. Ever four days, tumor’s major axis (a) and minor axis (b) was measured with a vernier caliper. Tumor volume (V) was then calculated according to the following equation: V=axb2/2. At the same time, their body weight was also weighed. When their tumor volume became about 300 mm3, these mice were randomized into five groups with 8 mice in each group, which were normal saline, Tf-LP, ART, ART-LP and Tf-ART-LP group, respectively. All reagents

Figure 1. Size distribution of Tf-ART-LPs.

Figure 2. Stability of Tf-ART-LPs.

Figure 3. Accumulative releasing ratio of ART in Tf-ART-LP.


22048 Int J Clin Exp Med 2015;8(12):22045-22052

were administered via caudal vein. According to tumor volume, a relative growth curve was drawn. After one month’s treatment, these mice were euthanized. Pathological changes of major organs like heart, liver, spleen, lung and kidney collected were observed by HE staining.

Statistical analysis

Measurement data were expressed by mean ± SD. Comparison results between two samples were expressed by LSD test. P<0.05 indicated

that there was statistically significant differ-ence, while P<0.01 suggested that there was statistically extremely significant difference. All statistical analyses were completed by the sta-tistical software SPSS17.0.

Results

Characterization of Tf-ART-LPs

As shown in Figure 1, the diameter of Tf-ART-LPs ranged from 84.5 nm to 100 nm, with a mean diameter of 94.2 nm. Tf-ART-LPs were placed at room temperature for 14 days and their average diameter was measured on day 0, 1, 3, 5, 7, 9 and 14, respectively. The results presented in Figure 2 showed that the average diameter of Tf-ART-LPs was about 94 nm. It indicated that no aggregation happened to Tf-ART-LPs during a certain period of time. Tf-ART-LPs were of good stability. The encapsu-lation efficiency of ART was found to be 85.9%. In normal saline at 37°C, ART could be released from liposomes slowly. The highest release rate was 58.7±2.9% after 48 hs (Figure 3).

Test on the targeting property of Tf-ART-LPs

ART-LPs and Tf-ART-LPs marked by FITC were incubated with U87 cells at 37°C for 3 h, re-

Figure 4. In-vitro test on the U87 cells targeting property of Tf-ART-LPs.

Figure 5. Statistical results of cellular uptake of Tf-ART-LPs. **P<0.01, compared with ART-LP group.


22049 Int J Clin Exp Med 2015;8(12):22045-22052

spectively. Their fluorescent microphotograph and statistical results were shown in Figures 4 and 5. These figures suggested that Tf-ART-LPs were uptaken by U87 cells significantly. The uptake rate reached up to 59.8±3.8%. By con-trast, fewer ART-LPs were uptaken and fluores-cence positive cells accounted for only 18.7± 4.5%. These results showed that the modifica-tion of Tf markedly increased the affinity of lipo-somes for U87 cells.

The effect of Tf-ART-LPs for treating tumors in-vitro

First of all, the impact of blank LPs and Tf-LPs on cell viability was detected. As shown in Figures 6, 7, no reduction of cell viability was observed after 0-100 ug/ml LPs and Tf-LPs were

incubated with cells for 24 hours. It proved that blank lipid carriers almost had no toxicity. However, when ART was encapsulated, a con-centration-dependent reduction of cell viability was observed after cells were treated with 0-40 ug/ml ART-LPs (P<0.05). Compared with ART-LPs of the same concentration, Tf-ART-LPs modified by Tf had a better killing effect. These results showed that Tf-ART-LPs could transport more ART actively into cells and thus took effect.

The in-vivo study on the therapeutic effect of Tf-ART-LPs

A subcutaneously implanted tumor model of human glioma cells in nude mouse was estab-lished and the tumor formation rate reached up to 100%. Figure 8 showed the ratio of tumor volume after and before administration. Four

Figure 6. Cytotoxicity of LPs.

Figure 7. Cytotoxicity of Tf-ART-LPs.

Figure 8. Effect of Tf-ART-LPs on tumor volume.

Figure 9. Effect of Tf-ART-LPs on mice weight.


22050 Int J Clin Exp Med 2015;8(12):22045-22052

days after administration, tumor volume of mice in the normal saline, Tf-LP, ART and ART-LP groups tended to increase gradually, while that of Tf-ART-LP group decreased instead. As time went by, tumor volume of mice in the nor-mal saline, Tf-LP, ART and ART-LP groups fur-ther increased day by day, whereas that of Tf-ART-LP group was inhibited or even eliminat-ed. These results showed that Tf-ART-LPs, after entering into mouse body, could enable more ART to target tumor and give full play of their anti-tumor effect. As shown in Figure 9, no obvi-ous reduction of body weight was observed dur-ing administration, which suggested that all drugs had no evident toxicity. Photographs of pathological sections of major organs by HE staining were presented in Figure 10. No signifi-

cant damage was found after caudal injection of LPs and ART-LPs.

Discussions

Human glioma is the most common intracranial primary malignant tumor with high mortality rate. Glioma has an infiltrative growth and ill-defined site compared with surrounding normal brain tissues. It is hard to be removed thor-oughly by surgery and tends to have postopera-tive residual. Further, it is insensitive to radio-therapy. Thus, the prognosis of patients with malignant glioma is very poor. The recurrence rate is very high even after comprehensive treatments like combined radiotherapy after operation [12]. Moreover, chemotherapy, due

Figure 10. HE staining images (×400) of the heart, liver, spleen, lung and kidney.


22051 Int J Clin Exp Med 2015;8(12):22045-22052

to a lack of good targeting property, can not achieve good therapeutic effect owing to low local drug concentration. Besides, high concen-tration drugs have higher toxicity. Therefore, it is imperative to find out a new treatment meth-od. Nanoliposomes, as a new type of drug car-rier, can be released slowly as well as reduce drug dosage and adverse reactions. Further- more, they are of no toxicity and immunosup-pressive effect on human body. Thus, they can be used as carriers of anti-tumor drugs to pro-long the circulation time of drugs in blood and enable drugs to aggregate at tumor sites to take effect [13, 14].

Transferrin is a member of the family of iron-binding proteins. Transferrin receptors are essential for cell proliferation. They are over-expressed on the surface of malignant tumor cells, including glioma. In normal tissue cells, their expression level is extremely low. Thus, it has always been considered as an ideal thera-peutic target [15, 16]. Transcytosis mediated by transferrin has been proved to be able to transport across the blood brain barrier, so nano-carriers coupled by transferrin has a potential glioma targeting property. Hereby, transferrin is believed to be a very potential molecular therapeutic target for treating glioma [17, 18].

In this study, an active targeting nano-scale anti-tumor drug was prepared by using lipo-somes modified with transferrin as the carrier of artesunate. With fluorescence microscopy, it was observed that artesunate nanolipo-somes modified with transferrin (with an aver-age diameter of 95 nm) could target glioma U87 cells effectively and enter into cytoplasm. The results of an in-vitro test on cell viability indicated that artesunate nanoliposomes mod-ified with transferrin had a better killing effect compared with those without modification of transferrin. This should be the result of active targeting of transferrin, which transported arte-sunate into cells efficiently and took effect. The anti-tumor effect in-vivo also indicated their good tumor inhibitive effect.

In conclusion, we prepared spherical artesuna-te nanoliposomes modified with transferrin in this study. With good active targeting property and anti-tumor effect both in-vitro and in-vivo, they will be a good alternative for treating human glioma.

Disclosure of conflict of interest

None.

Address correspondence to: Xinguang Yu, Depart- ment of Neurosurgery, PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. E-mail: [email protected]

References

[1] Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M; Comparative Risk Assessment collaborating group (Cancers). Causes of can-cer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366: 1784-1793.

[2] Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106-130.

[3] Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.

[4] Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diag-nosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.

[5] Tohme R, Le Moigne R, Przychodzen BP, et al. Inhibition of p97 with the first-in-class small molecule CB-5083: a novel strategy for acute myeloid leukemia therapy. Blood 2014; 124: 3766-3766.

[6] Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subse-quent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012; 119: 5133-5143.

[7] Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G, Li H, Gan X, Zhou H, Tang J, Xu G, Huang L, Zhang X, Fang Y, Wang K, Zheng S, Huang W, Xu R. CaMKII γ, a critical regulator of CML stem/pro-genitor cells, is a target of the natural product berbamine. Blood 2012; 120: 4829-4839.

[8] Kim C, Lee JH, Kim SH, Sethi G, Ahn KS. Arte- sunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leu-kemia xenograft mouse model. Oncotarget 2015; 6: 4020.


22052 Int J Clin Exp Med 2015;8(12):22045-22052

[9] Yang JS, Liu CW, Ma YS, Weng SW, Tang NY, Wu SH, Ji BC, Ma CY, Ko YC, Funayama S, Kuo CL. Chlorogenic acid induces apoptotic cell death in U937 leukemia cells through cas-pase-and mitochondria-dependent pathways. In vivo 2012; 26: 971-978.

[10] Yang J, Li J, Sun M, Chen K. Studies of tradi-tional Chinese medicine monomer on HeLa cell of cervical cancer. Pak J Pharm Sci 2014; 27 Suppl 4: 1063-1068.

[11] Lan G, Wang Q, Bin B. Investigation of Powder of Tangerine seed and Curcuma zedoary on chronic epididymitis. Hebei Journal of Tradi- tional Chinese Medicine 2013; 8: 51.

[12] Chen C, Chen Y, Hsi YT, Chang CS, Huang LF, Ho CT, Way TD, Kao JY. Chemical constituents and anticancer activity of Curcuma zedoaria roscoe essential oil against non-small cell lung carcinoma cells in vitro and in vivo. J Agric Food Chem 2013; 61: 11418-11427.

[13] Shiobara Y, Iwata T, Kodama M, et al. Biomi- metic transformation of dehydrocurdione into curcumenol and isocurcumenol and their ste-reochemistries. Tetrahedron Lett 1985; 26: 913-916.

[14] Xu L, Xu X, Cheng P. Treatment effect reaserch on gastric tumor by cancer cell vaccine modi-fied with Curcumol. J Pract Oncol 2007; 2: 007.

[15] Qian Y, Kang J, Wen T, et al. Content Deter- mination of Kaempferol in Kaempferol Gastric Floating Sustained-release Tablets by HPLC. China Pharmacy 2010; 41: 032.

[16] Lin H, Li X. L1210 Cell Apoptosis Induced by Curcumenol. China Pharmacy 2008; 30: 007.

[17] Lakshmi S, Padmaja G, Remani P. Antitumour effects of isocurcumenol isolated from Curcu- ma zedoaria rhizomes on human and murine cancer cells. Int J Med Chem 2011.

[18] O’Donnell MR, Abboud CN, Altman J, Appel- baum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G,Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. Acute myeloid leukemia. J Natl Compr Canc Netw 2012; 10: 984-1021.

original article on the preparation of transferrin ...on the preparation of transferrin modified...

Documents